ZF2001(商品名:智克威得、RBD-Dimer)是一款基于重组刺突蛋白(CHO细胞)技术的2019冠状病毒病疫苗,由安徽智飞龙科马生物制药、中国科学院微生物研究所联合研发。截至2020年12月,疫苗已在中国大陆、厄瓜多尔、马来西亚、巴基斯坦和乌兹别克斯坦招募29,000名参与者开展三期临床试验。疫苗采用重组DNA技术,以冠状病毒刺突糖蛋白(S...
智飞疫苗ZF2001(RBD-Dimer).已列入世界卫生组织授权名单!!! 查看图片 $智飞生物(SZ300122)$国外的疫苗策略从安全性上是不去蛋白苗的,最近又是因为致死在多国面临停止接种。国内想大规模接种,光靠国药和科兴的灭活苗产能是远远跟不上的。智飞的蛋白苗这个时候获批真的是及时。 Jackshen88 2021-03-18 16:35...
A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5SARS-CoV-2OmicronZF2001RBD-dimervaccineABSTRACTdoi:10.1080/22221751.2023.2179357Minrun DuanHuixin Duan...
Therefore, we sought to further improve our RBD-dimer-based protein subunit COVID-19 vaccine through use of the SWE adjuvant. In this study, we evaluated the effect of SWE in adjuvanting the RBD-dimer immunogen in mice. SWE largely improved both the humoral and cellular immune responses of ...
S2d). Therefore, I-R-F overcomes the poor immunogenicity of monomeric RBD, further improves the immunogenicity of RBD dimer and RBD-Fc, and induces long-lasting NAbs without side effects. A single or low dose of I-R-F induces robust NAbs even with no additional adjuvant To determine the ...
Therefore, using the chimeric approach, we rapidly developed the Delta-Omicron RBD-dimer vaccine. The antigenic integrity and cryoelectron microscopy (cryo-EM) structure were determined; the immunogenicity and protective efficacy were further evaluated, demonstrating the advantage and generalizability of ...
本研究以Delta-Omicron嵌合RBD二聚体为免疫原, 对广泛使用的3个疫苗平台(重组蛋白亚单位疫苗、腺病毒载体疫苗和mRNA疫苗)进行了免疫原性头对头比较, 通过小鼠模型比较了它们同源接种和序贯接种所诱导的体液免疫和细胞免疫反应的差异. 结果显示, 小鼠在免疫同源的两剂疫苗后, mRNA疫苗诱导的结合抗体和中和抗体滴度都最...
SARS-CoV-2 at the serum dilution ranged from 1:1000 to 1:3000 after two-dose injection, which performing better than other RBD vaccine formulations (Fig.1j). As expected, formulation with CpG enhanced nAb titers induced by RBD206-sc-dimer compared with immunizations with non-formulated ...
The results showed that plasmid with receptor binding domain (RBD) dimer‐Fc fusing antigen (2RBD‐Fc) induced the highest level of RBD‐specific IgG and neutralizing antibodies in mice. Then 2dRBD‐Fc and 2omRBD‐Fc vaccines, respectively derived from delta and omicron VOCs, were constructed....
Recently, we developed a recombinant COVID-19 vaccine (V-01) containing fusion protein (IFN-PADRE-RBD-Fc dimer) as antigen verified to induce protective immunity against SARS-CoV-2 challenge in pre-clinical study, which supported progression to Phase Ⅰ clinical trials in humans. A Randomized,...